Rare disease drug varieties approved

RecordSTO-NAEE4RMBKC-EWWVM3ZC0P-1MS13R

39

China · 2024

Rare disease drug varieties approved in China was 39 in 2024 (State Council).

Original source

New drug approvals in China: every year, the rank and how it is measured

Publisher
State Council
Authority tier
T1 Official
Retrieved
17 Sep 2026
Status
Verified

What the source says

不只注射用利纳西普,据罕见病信息网统计,全年批准罕见病用药39个品种,覆盖了34种罕见病。

Checked: the figure 39is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

State Council of China. (2024). 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202501/content_6997982.htm. Via StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R

Other formats: MLA, Chicago, BibTeX
MLA
State Council of China. "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网." 2024, https://www.gov.cn/zhengce/202501/content_6997982.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R.
Chicago
State Council of China. "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网." 2024. https://www.gov.cn/zhengce/202501/content_6997982.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R.
BibTeX
@misc{statecouncil2024rare1ms13r, author = {{State Council of China}}, title = {全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市\_政策解读\_中国政府网}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R}, note = {Original source: https://www.gov.cn/zhengce/202501/content\_6997982.htm. Accessed September 17, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of custody
Record: STO-NAEE4RMBKC-EWWVM3ZC0P-1MS13R T1 Official

Primary source

Publisher
State Council of China · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网
Type
Press release
Published
—
Locator
更好满足临床急需
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification

Status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Permanent URL
/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R